Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (May 2023)
25 slides from Genetic Technologies's investor presentation, May 2, 2023
Slide 1: Updated Investor Presentation and Investor Webinar
ASX Market Announcement Updated Investor Presentation and Investor Webinar Melbourne, Australia, 2 May 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to provide shareholders with
Slide 2: Forward Looking Statements
Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk fac
Slide 3: Genetic Technologies – Investor Webinar
For personal use only Genetic Technologies – Investor Webinar The Future: Unlocking personalised preventative medicine 2 May, 2023 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 4: World leading portfolio
World leading portfolio Most comprehensive guideline driven For personal use only portfolio for human and animal health. • Patented GeneType Multi Risk Test • Non-Invasive Prenatal Testing (NIPT) • Carrier screen testing • Pharmacogenomics • Oncogenetic diseases • Pet care Revenues anchored by our 3
Slide 5: Comprehensive genomics-based testing via a multi-brand strategy
Comprehensive genomics-based testings via a multi-brand strategy For personal use only Medical & Payer Consumer initiated Direct to Consumer Business to testing (CIT) Testing (DTC) Business (B2B) with medical supervision with no medical supervision [insert Oncology revenue structure – GTG [insertCar
Slide 6: Global Overview
Global Overview For personal use only 57 40 25 Employees Countries Patents globally Granted* (9 Pending Worldwide*) 14 51 12 Test Tests Partner Categories Laboratories 4 * Patents granted are specific to the GeneType portfolio of products
Slide 7: Snapshot and Achievements last months
Snapshot and Achievements last 12 months For personal use only GeneType commercialization EasyDNA & Affinity DNA Reimbursement activation ✓ 9 Tests NOW commercially available in the US ✓ Completed 2 Acquisitions ✓ Independently developed Budget Impact the geneType Multi-Risk test Model (BIM) identif
Slide 8: Delivering Revenue and Growth – Q3 FY23
Delivering Revenue and Growth – Q3 FY23 Cash Receipts (A$'000) 45% Q3 CASH RECEIPTS CASH BALANCE For personal use only $6,687 Growth on LY A$2.2m A$10.5m* half-year ending$4,626 December $2,232 31, 2021 $1,967 GROSS MARGIN March GROSS MARGIN Q3 FY22 Q3 FY23 YTD FY22 YTD FY23 A$1.13m 49% +2ppts Strat
Slide 9: Execute the B2B commercialisation of the geneType multi-risk test
Execute the B2B commercialisation of the geneType multi-risk test For personal use only Commercialisation of the geneType suite of multi-risk tests Commercialisation of the geneType suite of multi-risk tests Our FOCUS Demonstrate clinical validity & clinical utility of geneType tests Core ‘4’ EasyDN
Slide 10: NEW Comprehensive Breast and Ovarian Cancer test
NEW Comprehensive Breast and Ovarian Cancer test Evaluates a woman’s risk of developing Breast and/or Ovarian Cancer in women 30 years+ For personal use only 5% - Hereditary Cancer with known pathogenic variant BRCA1/2 10% - Familial cancer with no known pathogenic variant 85% - GeneType Patented in
Slide 11: NEW – Diseases now available in the US
NEW – 9 Diseases now available in the US GeneType can identify patients ’at risk’ before onset and aid in the early detection and treatment. GeneType Risk assessment test for breast cancer has demonstrated improved early stage detection by For personal use only 18% and saving approx. US$1.4B per ann
Slide 12: NEW – Peer Review Publications Released
NEW – 3 Peer Review Publications Released Our Scientific team continues to achieve scientific publication milestones, with 3 publications accepted in three peer-reviewed journals during the quarter 3 NEW Peer For personal use only reviewed Publications in the latest Qtr Cancer Prevention Research Va
Slide 13: NEW Strategic Alliance with Qiagen
NEW Strategic Alliance with Qiagen The alliance will establish and develop a ‘Centre of Excellence’ facility in Australia For personal use only QIAGEN will support the enhancement of GTG capabilities through software, hardware, consumable and technical solutions, including: • Reagents and QIAGEN’s p
Slide 14: GeneType Priority Pathway to Market
GeneType Priority Pathway to Market For personal use only Medical & Payer Payer coverage is the key driver of revenues for geneType Business to Coverage from payers in the US will accelerate adoption of Business (B2B) geneType Risk Assessment Tests more widely Revenue Budget Impact Model (BIM) demon
Slide 15: Economic Modeling in the US Payer System
Economic Modeling in the US Payer System1 The economic benefit to the payers in the US is US$1.4B per annum For personal use only $73 69% - 74% 6.8%-9.2% US Payor system overall increase in Supplemental will save per women getting screening frequency patient per year screened 14.8% - 8.8% 57% - 67%
Slide 16: DTC - Growth strategy for EasyDNA
DTC - Growth strategy for EasyDNA For personal use only PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus [insert revenue structure and [insert revenue structure and agreement types] Brand Refreshagreement Website types] Refresh Improved Lead Gen New Sales Channels Product list Product list
Slide 17: eCommerce Growth strategy for EasyDNA
eCommerce Growth strategy for EasyDNA For personal use only 15
Slide 18: Thank you
For personal use only Thank you Investor Relations Adrian Mulcahy Market Eye – Automic Group www.linkedin.com/company/genetype-limited M: +61 438 630 422 E: adrian.mulcahy@automicgroup.com.au www.genetype.com 16
Slide 19: Appendices
For personal use only Appendices 17
Slide 20: Board and Management
Board and Management: Sales and Scientific expertise leading GTG For personal use only Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Comm, FAICD, FCA, Chairman Non – Executive Director FGIA, FTIA, F Fin Non – Executive Director Non – Executive Director Dr. Jerzy “George”
Slide 21: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board For personal use only Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, MWGO is Principal Fellow and Reg
Slide 22: Financial Overview
Financial Overview For personal use only • Net cash outflow of A$7.2 million for the nine months to 31 March 2023. We continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialise our geneType tests • Cash reserves will be directed to: A$’000 31-March-23 31-March-22 Change • to
Slide 23: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 25 April 2023 0.3c ADR price (USD) as at 25 February 2023 $1.06 Other, 24% Ord Shares on Issue (M) 11,542 ASX 5
Slide 24: Our Intellectual Property
Our Intellectual Property For personal use only 4 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of • Breast cancer risk assessment assessing risk of developing a severe • Methods for assessing risk of developing prostate cancer response to Coronavirus infect
Slide 25: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score
Genetic Technologies — Investor Presentation (May 2023) on 6ix